AR121918A1 - Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados - Google Patents
Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivadosInfo
- Publication number
- AR121918A1 AR121918A1 ARP210101087A ARP210101087A AR121918A1 AR 121918 A1 AR121918 A1 AR 121918A1 AR P210101087 A ARP210101087 A AR P210101087A AR P210101087 A ARP210101087 A AR P210101087A AR 121918 A1 AR121918 A1 AR 121918A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr
- seq
- amino acid
- acid sequence
- per total
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 150000004676 glycans Chemical class 0.000 abstract 5
- 239000006143 cell culture medium Substances 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000004962 mammalian cell Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 2
- 229920001503 Glucan Polymers 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 1
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a proteínas, en particular, anticuerpos, tales como anticuerpos biespecíficos anti-CD20 / anti-CD3 y anticuerpos anti-a-sinucleína, que tienen glucanos monogalactosilados (G1) y digalactosilados (G2). Más en particular, la presente invención se refiere a ingeniería de galactosilación para generar proteínas con propiedades terapéuticas mejoradas, que incluyen proteínas con título aumentado. Además, la invención se refiere a un medio de cultivo celular y una célula de mamífero, así como a métodos que usan dicho medio de cultivo celular y dicha célula de mamífero para producir dichas proteínas. Además, la presente invención se refiere al uso de dichos anticuerpos como un medicamento, tal como para el tratamiento de cáncer, en particular, cáncer asociado a linfocitos B, o enfermedad de Parkinson. Reivindicación 1: Un anticuerpo anti-a-sinucleína que tiene glucanos monogalactosilados (G1) y digalactosilados (G2), en donde el anticuerpo anti-a-sinucleína comprende un dominio variable de la cadena pesada (VH) que comprende (a) CDR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 10, (b) CDR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 11 y (c) CDR-H3 que comprende la secuencia de aminoácidos de SEQ ID Nº 12; y un dominio variable de la cadena liviana (VL) que comprende (d) CDR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 13, (e) CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 14 y (f) CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 15; y en donde el anticuerpo anti-a-sinucleína tiene 17,2 - 48,0% (p/p) de G1 y 3,1 - 15,0% (p/p) de G2 por glucano total; preferentemente, 25,4 - 48,0% (p/p) de G1 y 3,5 - 15,0% (p/p) de G2 por glucano total; preferentemente, 27,2 - 47,0% de G1 y 4,4 a 15,0% de G2 por glucano total; preferentemente, 40,0 - 46,0% (p/p) de G1 y 8,4 - 15,0% (p/p) de G2 por glucano total; más preferentemente, 41,0 - 45,0% (p/p) de G1 y 9,5 - 14,0% (p/p) de G2 por glucano total y, con máxima preferencia, 42,1 - 43,9% (p/p) de G1 y 10,6 - 13,3% (p/p) de G2 por glucano total. Reivindicación 8: Un método para producir un anticuerpo contra a-sinucleína de acuerdo con cualquiera de las reivindicaciones 1 a 3 que tiene glucanos monogalactosilados (G1) y digalactosilados (G2), en donde dicho método comprende: (a) cultivar una célula de mamífero en un medio de cultivo celular, en donde una concentración de al menos más de 4,0 y menos de 10,0 mM de grupo(s) sulfhidrilo de uno o más compuestos de sulfhidrilo y al menos más de 3,0 g/l de glucosa en el medio de cultivo celular se mantienen durante al menos 3, más preferentemente, durante al menos 4 y, aún más preferentemente, durante al menos 5 días, (b) aislar dicho anticuerpo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20171356 | 2020-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121918A1 true AR121918A1 (es) | 2022-07-20 |
Family
ID=70464886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101087A AR121918A1 (es) | 2020-04-24 | 2021-04-23 | Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230265204A1 (es) |
| EP (2) | EP4139349A1 (es) |
| JP (3) | JP2023522417A (es) |
| KR (1) | KR20230005172A (es) |
| CN (1) | CN115427443A (es) |
| AR (1) | AR121918A1 (es) |
| AU (1) | AU2021258475A1 (es) |
| BR (1) | BR112022021203A2 (es) |
| CA (1) | CA3178472A1 (es) |
| CL (2) | CL2022002885A1 (es) |
| CR (2) | CR20220531A (es) |
| IL (1) | IL296664A (es) |
| MX (1) | MX2022013173A (es) |
| PE (1) | PE20230078A1 (es) |
| SA (1) | SA522441031B1 (es) |
| WO (1) | WO2021214277A1 (es) |
| ZA (1) | ZA202210643B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3334167A1 (de) | 1983-09-21 | 1985-04-04 | Siemens AG, 1000 Berlin und 8000 München | Halbleiterdiode |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| EP0700521B1 (en) | 1993-05-28 | 2003-06-04 | Baylor College Of Medicine | Method and mass spectrometer for desorption and ionization of analytes |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| JP2002502086A (ja) | 1998-01-23 | 2002-01-22 | アナリティカ オブ ブランフォード インコーポレーテッド | 表面からの質量分光測定 |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| EP1467615B2 (en) * | 2001-12-27 | 2017-03-22 | GlycoFi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| RS58217B1 (sr) | 2007-04-03 | 2019-03-29 | Amgen Res Munich Gmbh | Interspecijski specifičan vezujući domen |
| TR201816045T4 (tr) | 2007-10-12 | 2018-11-21 | Hoffmann La Roche | Birden fazla nükleik asitten protein ekspresyonu. |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| KR20110013687A (ko) | 2009-08-03 | 2011-02-10 | 삼성모바일디스플레이주식회사 | 유기전계발광표시장치 및 그의 구동방법 |
| US20120302737A1 (en) | 2009-09-16 | 2012-11-29 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| CN103796679B (zh) | 2011-06-23 | 2016-10-19 | 比奥根国际神经科学公司 | 抗-α突触核蛋白结合分子 |
| EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| US20130058936A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| LT2771031T (lt) | 2011-10-28 | 2018-08-27 | Prothena Biosciences Limited | Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną |
| MX360778B (es) | 2012-01-27 | 2018-11-16 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen alfa-sinucleína. |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| WO2015075635A2 (en) * | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| MY176237A (en) | 2013-11-21 | 2020-07-24 | Hoffmann La Roche | Anti-alpha-synuclein antibodies and methods of use |
| SI3110961T1 (sl) * | 2014-02-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina |
| ES2979976T3 (es) | 2014-08-04 | 2024-09-27 | Hoffmann La Roche | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3583124A1 (en) * | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| MX2019014274A (es) * | 2017-06-02 | 2020-01-23 | Hoffmann La Roche | Metodo de tratamiento. |
| EP3658584A1 (en) * | 2017-07-26 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody |
| CN112839710B (zh) * | 2018-08-09 | 2024-09-17 | 霍夫曼-拉罗奇有限公司 | 帕金森氏病的确定 |
-
2021
- 2021-04-23 US US17/996,807 patent/US20230265204A1/en active Pending
- 2021-04-23 CR CR20220531A patent/CR20220531A/es unknown
- 2021-04-23 EP EP21719678.1A patent/EP4139349A1/en active Pending
- 2021-04-23 CA CA3178472A patent/CA3178472A1/en active Pending
- 2021-04-23 AR ARP210101087A patent/AR121918A1/es unknown
- 2021-04-23 CN CN202180029319.5A patent/CN115427443A/zh active Pending
- 2021-04-23 AU AU2021258475A patent/AU2021258475A1/en active Pending
- 2021-04-23 JP JP2022564304A patent/JP2023522417A/ja active Pending
- 2021-04-23 PE PE2022002437A patent/PE20230078A1/es unknown
- 2021-04-23 MX MX2022013173A patent/MX2022013173A/es unknown
- 2021-04-23 EP EP24168363.0A patent/EP4400515A3/en active Pending
- 2021-04-23 IL IL296664A patent/IL296664A/en unknown
- 2021-04-23 BR BR112022021203A patent/BR112022021203A2/pt unknown
- 2021-04-23 CR CR20250142A patent/CR20250142A/es unknown
- 2021-04-23 KR KR1020227036931A patent/KR20230005172A/ko active Pending
- 2021-04-23 WO PCT/EP2021/060637 patent/WO2021214277A1/en not_active Ceased
-
2022
- 2022-09-26 ZA ZA2022/10643A patent/ZA202210643B/en unknown
- 2022-10-18 CL CL2022002885A patent/CL2022002885A1/es unknown
- 2022-10-24 SA SA522441031A patent/SA522441031B1/ar unknown
-
2025
- 2025-01-07 CL CL2025000038A patent/CL2025000038A1/es unknown
- 2025-02-05 JP JP2025017484A patent/JP2025072512A/ja active Pending
- 2025-07-16 JP JP2025119872A patent/JP2025157400A/ja active Pending
- 2025-07-29 US US19/284,044 patent/US20250353922A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3178472A1 (en) | 2021-10-28 |
| US20250353922A1 (en) | 2025-11-20 |
| MX2022013173A (es) | 2022-11-30 |
| EP4139349A1 (en) | 2023-03-01 |
| CR20220531A (es) | 2022-11-28 |
| AU2021258475A1 (en) | 2022-10-20 |
| WO2021214277A1 (en) | 2021-10-28 |
| IL296664A (en) | 2022-11-01 |
| CL2022002885A1 (es) | 2023-06-16 |
| EP4400515A2 (en) | 2024-07-17 |
| ZA202210643B (en) | 2023-06-28 |
| JP2025157400A (ja) | 2025-10-15 |
| SA522441031B1 (ar) | 2025-05-15 |
| CL2025000038A1 (es) | 2025-05-23 |
| TW202206459A (zh) | 2022-02-16 |
| KR20230005172A (ko) | 2023-01-09 |
| BR112022021203A2 (pt) | 2022-12-06 |
| JP2025072512A (ja) | 2025-05-09 |
| US20230265204A1 (en) | 2023-08-24 |
| CN115427443A (zh) | 2022-12-02 |
| CR20250142A (es) | 2025-10-30 |
| EP4400515A3 (en) | 2024-10-23 |
| PE20230078A1 (es) | 2023-01-11 |
| JP2023522417A (ja) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014274215B2 (en) | Antibody locker for the inactivation of protein drug | |
| TWI688401B (zh) | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 | |
| AR121918A1 (es) | Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados | |
| KR101739620B1 (ko) | 특히, 대숙주성 이식편병(gvhd)을 예방하기 위한 항 cd4 항체 | |
| CO2018010919A2 (es) | Moleculas de unión b7-h3 novedosas, conjugados anticuerpo - fármaco de los mismos y métodos de uso de los mismos | |
| CY1115456T1 (el) | Μεθοδος χορηγησης αντισωματων αντι-ιl-5 | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| US20200079853A1 (en) | T regulatory cells and uses thereof | |
| AU2020307667A1 (en) | Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer | |
| RU2013105769A (ru) | Биологические материалы и их применение | |
| CN110856446A (zh) | 抗pd-l1抗体及其用途 | |
| EP4262988A1 (en) | Anti-nectin-4-antibodies and uses thereof | |
| WO2020232427A3 (en) | Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins | |
| KR20210075090A (ko) | Gm-csf 길항제를 이용한 면역요법-관련 독성의 치료 방법 | |
| MX2025000124A (es) | Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre | |
| EP2970468A1 (en) | Notch2 binding molecules for treating respiratory diseases | |
| US12065672B2 (en) | Methods for the production of therapeutic, diagnostic, or research antibodies | |
| US20210371514A1 (en) | Materials and methods for treating stress-related disorders and cancer | |
| TW202019962A (zh) | 標靶CD38及TGF-β的組合療法 | |
| JPWO2021214277A5 (es) | ||
| AR108139A1 (es) | Moléculas de unión b7-h3, conjugados anticuerpo fármaco de los mismos y métodos de uso de los mismos | |
| RU2024107254A (ru) | Модифицированное антитело против vegfr2 (kdr) и его применение | |
| NZ760655A (en) | Antibodies that modulate a biological activity expressed by a cell | |
| NZ766247A (en) | Monoclonal antibodies and methods for using same | |
| NZ733531A (en) | Bispecific antibodies against cd3 and cd20 |